Filing Flows › Seres Therapeutics (MCRB) › Q3 2026 › vs Q2 2026
Seres Therapeutics (MCRB) Q3 2026 vs Q2 2026 (quarter over quarter)
Seres Therapeutics's revenue fell $143K (-19%) from $736K in Q2 2026 to $593K in Q3 2026.
Seres Therapeutics, Q3 2026: revenue $593K (+69% year over year), net loss $16.3M, operating cash flow −$10.5M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $593K | $736K | −$143K | -19% |
| Net loss | $16.3M | −$4.6M | $20.9M | — |
| Costs & expenses | $16.9M | $26.6M | −$9.7M | -37% |
| Operating costs | $16.7M | $22.0M | −$5.3M | -24% |
| Interest & other, net | $134K | −$25.9M | $26.0M | — |
| Research & development | $5.6M | $9.1M | −$3.5M | -39% |
| General & admin | $5.4M | $7.1M | −$1.6M | -23% |
| Other operating costs | $5.7M | $5.8M | −$102K | -2% |
| Operating cash sources | $16.3M | −$4.6M | $20.9M | — |
| Depreciation & amortization | $481K | $670K | −$189K | -28% |
| Share-based compensation | $1.9M | $1.7M | $120K | +7% |
| Working capital & other | $3.5M | −$29.4M | $32.9M | — |
| Cash used in operations | $10.5M | $22.4M | −$11.9M | -53% |
| Net loss absorbed | $16.3M | −$4.6M | $20.9M | — |
Questions
How much did Seres Therapeutics's revenue grow quarter over quarter in Q3 2026?
Seres Therapeutics's revenue fell $143K (-19%) from $736K in Q2 2026 to $593K in Q3 2026.